Genomic Profiling Articles & Analysis
31 news found
As the practice worked with SOPHiA GENETICS throughout the year, it experienced the benefits of utilizing the SOPHiA DDM™ Platform for its next generation sequencing (NGS) testing and today announced it will begin to validate the SOPHiA DDM™ RNAtarget Technology and the SOPHiA DDM™ for Comprehensive Genomic Profiling (CGP) application. ...
SOPHiA GENETICS offers a comprehensive suite of liquid biopsy applications that have helped progress oncology research and tumor mutation profiling. Liquid biopsy testing offers an alternative to solid tumor testing by isolating cell-free DNA (cfDNA) from blood plasma, which may uncover circulating tumor DNA (ctDNA). This non-invasive testing allows for cancer ...
Data computed daily by the Platform has surged over the years with over 1.8 million genomic profiles being analyzed on the platform, at a rate of almost 30,000 analyses per month. ...
CD Genomics, a trailblazing genomics and bioinformatics services provider, is delighted to announce the launch of the Long Amplicon Analysis (LAA) service, a mature genomic research method that promises to revolutionize the field. ...
Researchers at Dana-Farber Cancer Institute showed that enumeration of circulating tumor cells (CTCs) with Menarini Silicon Biosystems’ CELLSEARCH® System and the CELLSERCH® Circulating Multiple Myeloma Cell (CMMC) Test* can be used to monitor and manage patients with Multiple Myeloma (MM) even at asymptomatic precursor stages Menarini Silicon Biosystems, a pioneer of liquid biopsy ...
Patient cohorts are selected from the Cellworks patient database of 100,000+ omics profiles of patients based on guidance from the client. Cellworks creates an in silico model of the drug or drug combination. ...
” Cellworks Therapy Biosimulation The Cellworks Platform biosimulates how a patient's personalized genomic disease model will respond to therapies prior to treatment and can also identify novel drug combinations for treatment-refractory patients. ...
By applying advanced AI algorithms to immunomorphological cellular profiles and altered genome-wide DNA characteristics, the company is developing a new class of highly sensitive and specific non-invasive tests intended for widespread adoption. ...
OncoDNA’s extensive experience in genomic profiling for precision oncology has been translated into a relevant gene panel and associated interpretation tools. ...
The move to Eagle Genomics is a logical step for Tarun, who has most recently served as co-CEO and CTO at Humans For AI, a non-profit organization focused on social good and diversity in AI. ...
This testing service will provide essential genomic information through comprehensive genomic profiling (CGP) for patients with any solid cancerous tumor. ...
“We are pleased that Medicare has taken this important step to make complete genomic profiling more widely available for patients with advanced cancers,” said Helmy Eltoukhy, Guardant Health co-CEO. ...
” “We are pleased to collaborate with a widely-utilized and experienced laboratory like Foundation Medicine to ensure broad access to high quality, comprehensive genomic profiling for cancer patients who do not have access to such testing in their home institutions,” said Anthony (Nino) Sireci, M.D., Vice President, Clinical Biomarkers and ...
An exploratory analysis from the PREDATOR study of metastatic colorectal cancer (mCRC) patients undergoing surgicalAuthors (in order): Halla Nimeiri1, Amanda Young1, Russell Madison1, Alexander Fine1, Ole Gjoerup1, Fotios Loupakis2, Matteo Fassan2,3, Sara Lonardi2, Shruti Sharma4, Hsin-Ta Wu4, Alexey Aleshin4, Elise Renkonen1, Priti Hegde11Foundation Medicine Inc, 2Istituto Oncologico Veneto ...
” Full List of Guardant Health Presentations: Impact of postoperative integrated genomic and epigenomic signatures of circulating tumor DNA (ctDNA) on recurrence in resected colorectal cancer: Initial report of a prospective ctDNA monitoring study COSMOS-CRC-01 (Abstract 168) Clinical utility of microsatellite instability (MSI-H) identified on liquid biopsy in advanced ...
It can detect the precise positions of ribosomes to determine which mRNAs are being actively translated, which allows for the profiling of the active ribosomes in a cell at a particular moment, as well as the location of the translation initiation sites, the complement of translated ORFs, the specific locations of ribosomes on the mRNA, and the translation rate of ...
In addition, biosimulation is emerging as an essential tool to improve the success rate of clinical trials and speed the development of lifesaving medicines for the patients that need them. “From comprehensive genomic inputs, the Cellworks Biosimulation Platform identifies pathway based polygenic biomarkers that predict the efficacy of novel drug combinations and new drugs ...
This approval makes FoundationOne®CDx the only comprehensive genomic profiling (CGP) test approved as a companion diagnostic across two groups of targeted therapies, representing an important step toward simplifying decision making for oncologists. ...
TG4050 appears to demonstrate a favorable safety profile thus far. We have also confirmed the feasibility of the ‘needle to needle’ process with these two multicenter international Phase I trials, using our own manufacturing facility. ...
Under the new agreements, TRICARE beneficiaries now have improved access to Foundation Medicine’s FDA-approved comprehensive genomic profiling (CGP) tests, FoundationOne®CDx and FoundationOne®Liquid CDx, in accordance with their approved indications for all solid tumors. ...